Reality beat their plan and they're leaning in: recent realized upside surprise, response underway, drivers still live
The model's full reasoning — Q3 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: On this call, does management recount that something REAL in the recent period turned out BETTER THAN THE COMPANY ITSELF HAD EXPECTED OR PLANNED — and is the company ALREADY responding to that favorable surprise in some visible way, with the cause of the surprise described as still in effect rather than finished? We need to find if management explicitly or plainly indicates that actual recent events exceeded the company's own prior expectation, plan, assumption, or timeline. And then a response already visible, and the cause still running. Let's scan the transcript for phrases like "ahead of expectations", "better than expected", "faster than planned", etc. Dan Passeri: "The data bolsters our belief that the demonstrated mechanism of action and resulting in activation and amplification of cancer-specific T cells will mechanistically complement and enhance therapeutic benefit derived from checkpoint inhibition, such as PD-L1 inhibitor KEYTRUDA." Not a surprise. Anish Suri: "We believe, as supported by our clinical data that this approach is differentiated in terms of both safety and efficacy outcomes over other modalities that attempt to activate the immune system in a nonselective manner." Not a surprise. Ken Pienta: "We're pleased to be presenting our updated data from the ongoing CUE-101 Phase I trial, as both a single-agent monotherapy and third line and beyond patients as well as the encouraging emerging data from the combination study with pembrolizumab in first-line patients." Not a surprise. Matteo Levisetti: "At the presumed recommended Phase II combination dose, we have not only not observed any DLTs. We have observed a 40% objective response rate with 4 now confirmed partial responses and another 4 patients with stable disease that are currently being monitored on the trial. This compares favorably with the reported overall response rate of single-agent pembrolizumab of 19% in the first-line treatment setting as observed in the KEYNOTE 48 trial." That's a comparison to historical data, not to the company's own expectations.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| CW | Curtiss-Wright Corporation | Q1 2024 | 2024-05-02 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEP | American Electric Power Company, Inc. | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
TENB · Q2 2021 → YESThe question is about whether management recounts something real that turned out better than expected, and they're already responding to it, with the cause still in effect. YES The transcript shows management describing the Alsid acquisition as delivering a realized favorable surprise: customers and prospects received the identity and user permission vulnerability assessment "well received" and it led to "outperformance of our earlier expectations from the business." This concerns a real operating event (customer adoption and platform uptake) that already happened and exceeded the company's own prior expectations. Management is visibly responding by accelerating investments: they plan to continue adding quota capacity in the second half (more than in the first half) and to invest in sales and marketing, explicitly tied to the strong performance and confidence in the business.
CYBR · Q3 2021 → YESThe question is: Does management recount that something REAL in the recent period turned out BETTER THAN THE COMPANY ITSELF HAD EXPECTED OR PLANNED — and is the company ALREADY responding to that favo...YES Management describes a realized favorable surprise in the subscription transition: "we made strong progress and outperformed our expectations in the third quarter" and "subscription ARR growth accelerated to 131%," with "strong demand for our SaaS solutions" continuing to drive it. They are already responding visibly by accelerating the transition and realloc resources, resetting plans upward to exit by Q3 2022 instead of Q4, and raising the annual recurring revenue growth expectation from 35% to 37% based on record bookings. The cause remains in effect, as they note the acceleration and strong demand environment persisting into the year.
ET · Q2 2023 → YESThe question is: Does management recount that something REAL in the recent period turned out BETTER THAN THE COMPANY ITSELF HAD EXPECTED OR PLANNED — and is the company ALREADY responding to that favo...YES The transcript shows management describing a realized favorable surprise on the Enable acquisition: actual performance "exceed[s] anything that we ever expected," with results "significantly higher, a good probably 40% or 50% higher than what we were anticipating." They attribute part of the upside to ongoing commercial synergies being discovered daily as integration proceeds. Management is visibly responding by integrating the assets, actively identifying and implementing new commercial opportunities (new routes, blending, additions to move more throughput), and reallocating attention toward expanding volumes.